Partial spike gene sequencing for the identification of SARS-CoV-2 variants circulating in Cameroon in 2021
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.18155 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Chavely Gwladys Monamele und 13 weiteren Autor:innen. Beteiligte Einrichtung: Virology Service, Centre Pasteur of Cameroon; PO Box 1274, Yaounde, Cameroon. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Global monitoring of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) genetic sequences and associated metadata is essential for coronavirus disease 2019 (COVID-19) response. Therefore, Sanger's partial genome sequencing technique was used to monitor the circulating variants of SARS-CoV-2 in Cameroon. Methodology: Nasopharyngeal specimen was collected from persons suspected of SARS-CoV-2 following the national guidelines between January and December 2021. All specimens with cycle threshold (Ct) below 30 after amplification were eligible for sequencing of the partial spike (S) gene of SARS-CoV-2 using the Sanger sequencing method.
Results
During the year 2021, 1481 real time reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive samples were selected for partial sequencing of the S gene of SARS-CoV-2. Amongst these, 878 yielded good sequencing products. A total of 231 probable variants (26.3%) were identified. The variants were mainly represented by Delta (70.6%), Alpha (15.6%), Omicron (7.4%), Beta (3.5%), Mu (1.7%) and Gamma (0.4%). Phylogenetic analysis of the probable variants from Cameroon with reference strains confirmed that all prior and current variants of concern (VOC) clustered with their respective reference sequences.
Conclusions
The surveillance strategy implemented in Cameroon, based on partial sequencing of the S gene enabled identification of the major circulating variants and provided information on the distribution of these variants, which contributed to implementing public health measures to control disease spread in the country.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virology Service, Centre Pasteur of Cameroon; PO Box 1274, Yaounde, Cameroon.
- Epidemiology and Public Health Service, Centre Pasteur of Cameroon; PO Box 1274, Yaounde, Cameroon.
- Garoua Annex, Centre Pasteur of Cameroon; PO Box Garoua, Cameroon.
- Scientific Department, Centre Pasteur of Cameroon; PO Box 1274, Yaounde, Cameroon.
Zitieren
APA
Monamele, C. G., Sadeuh-Mba, S. A., Ilouga, P. V., Moumbeket, M. H. Y., Messanga, L. L. E., Mounchili Njifon, A., Madaha, E. L., Njankouo, R. M., Tagnouokam-Ngoupo, P. A., Tchatchueng, J. B. M., Tejiokem, M. C., Perraut, R., Eyangoh, S., & Njouom, R. (2024). Partial spike gene sequencing for the identification of SARS-CoV-2 variants circulating in Cameroon in 2021. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.18155
Vancouver
Monamele CG, Sadeuh-Mba SA, Ilouga PV, Moumbeket MHY, Messanga LLE, Mounchili Njifon A, et al. Partial spike gene sequencing for the identification of SARS-CoV-2 variants circulating in Cameroon in 2021. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.18155
BibTeX
@article{Monamele2024,
author = {Monamele, Chavely Gwladys and Sadeuh-Mba, Serge Alain and Ilouga, Pauliana Vanessa and Moumbeket, Moïse Henri Y and Messanga, Loique Landry E and Mounchili Njifon, Aristide and Madaha, Estelle L and Njankouo, Ripa M and Tagnouokam-Ngoupo, Paul Alain and Tchatchueng, Jules Brice M and Tejiokem, Mathurin Cyrille and Perraut, Ronald and Eyangoh, Sara and Njouom, Richard},
title = {Partial spike gene sequencing for the identification of SARS-CoV-2 variants circulating in Cameroon in 2021},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.18155}
}
EUVIMED